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Summary
Representational difference analysis (RDA) of human breast cancer was used to discover a novel amplicon located at
chromosomal region 8q24.3. We examined a series of breast cancer samples harboring amplification of this region and
determined that KCNK9 is the sole overexpressed gene within the amplification epicenter. KCNK9 encodes a potassium
channel that is amplified from 3-fold to 10-fold in 10% of breast tumors and overexpressed from 5-fold to over 100-fold
in 44% of breast tumors. Overexpression of KCNK9 in cell lines promotes tumor formation and confers resistance to both
hypoxia and serum deprivation, suggesting that its amplification and overexpression plays a physiologically important role
in human breast cancer.
Introduction four DNA probes that all originated from a 550 kb region of a
novel breast cancer amplicon. High-resolution mapping led to
the identification of a single overexpressed gene, KCNK9, thatAmplification of oncogenes such as HER2 and CCND1 is one
of the key genetic mechanisms underlying the development of was shown in functional studies to convey properties highly
consistent with a role in tumor formation.human breast cancer. The size of the genomic region sur-
rounding oncogenes that is amplified in tumors can vary consid-
erably, from 700 kb to 4.5 Mb for CCND1 and from 350 kb to Results
over 1 Mb for NMYC (Tanigami et al., 1992; Hiemstra et al.,
1994). Genes that are coamplified along with the “driver” gene We applied RDA to a series of breast tumor samples and tested
the resultant cloned sequences for their ability to detect geno-underlying selective amplification are often overexpressed
(Wimmer et al., 1999; Pollack et al., 2002). Consequently, over- mic amplification by DNA hybridization. From one particular
cancer sample, we isolated six RDA-derived sequences (RDAexpression of an amplified gene in and of itself is not convincing
evidence for a role in tumor formation. More compelling genetic probes) that detected amplification, two of which were mapped
by analysis of radiation-hybrid panels to the HER2 locus, andevidence for a gene’s candidacy as a “driver” gene comes from
high-resolution mapping of amplicon boundaries, which to date the other four of which were mapped to chromosomal region
8q24.3, approximately 10 Mb telomeric to the MYC oncogene.remains labor intensive and has been carried out in only a few
cases of reported candidate breast cancer-amplified onco- An initial survey of breast tumors by DNA hybridization showed
that the 8q24.3 RDA probes detected amplification (4-fold togenes, including ZNF217, CYP24, and PPM1D (Collins et al.,
1998; Albertson et al., 2000; Li et al., 2002). 10-fold) in 4 out of 70 primary breast tumors. Two of these four
tumors harboring amplification also showed 3-fold amplificationIn this report, RDA (Lisitsyn et al., 1995) was used to isolate
S I G N I F I C A N C E
Many of the genetic alterations that drive the development and progression of sporadic breast cancer remain poorly characterized.
Whole-genome approaches that can pinpoint relatively small genomic aberrations at high resolution allow identification of potentially
causative cancer genes. Here, RDA was used to find a 550 kb amplicon containing only one overexpressed gene, KCNK9. Functional
analysis of KCNK9 has established its ability to act as a dominant oncogene, making KCNK9 a potential target in treatment of tumors
presenting amplification and overexpression of KCNK9. Additionally, our finding that KCNK9 overexpression confers resistance to
hypoxia, together with its reported role in mediating other oxygen-sensitive physiological responses, opens up a potential new line
of investigation into the development of hypoxia tolerance in tumor cells.
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of MYC, whereas the other two tumors were not amplified for
MYC, indicating that amplification of this region can occur inde-
pendently. We performed a more extensive survey of primary
invasive breast cancers with quantitative PCR and determined
that 24 out of 247 breast tumors (approximately 10%) were
amplified for this locus (3-fold to 10-fold, data not shown).
As a first step to find the gene underlying the selective
amplification of this region, the four 8q24.3 RDA probes and
nearby sequence-tagged sites (STSs) were used to isolate hu-
man genomic DNA clones. These clones were sequenced and
the resultant genomic sequence was used to construct a map
of the amplified locus. To identify the amplification epicenter,
the genomic amplification status of STSs distributed across this
locus was determined in a set of five amplified tumors and
cancer cell lines. Two samples displayed equal copy number
increase (3-fold to 5-fold) throughout the 1.3 Mb region ana-
lyzed, suggesting that other genes outside of this region may
provide selective pressure for increased genomic copy number
in these tumors (data not shown). However, we identified a
clearly delineated 550 kb amplicon in the primary tumor from
which the RDA-derived sequences were obtained and an over-
lapping 700 kb amplicon in the breast cancer cell line ZR-75-
30 (Figure 1). This 550 kb amplified region was also present in
the broader amplicon of an additional primary tumor (Figure 1).
Figure 1. A 550 kb amplicon harboring KCNK9 at human chromosomal re-These results suggest that the common 550 kb amplified region
gion 8q24.3harbors a gene that when amplified provided a selective advan-
DNA copy number for two primary tumors (CHTN9 in blue and CHTN159 intage to the tumor cells.
green) and one cell line (ZR-75-30 in red) were determined by Q-PCR andTwo genes were identified within the 550 kb amplicon. One
plotted against their chromosomal 8 nucleotide position in megabases
of the genes, termed T1, was identified by exon trapping and (http://genome.ucsc.edu/, June 2002 freeze). Original RDA probes are indi-
subsequent cDNA cloning and is identical to the subsequently cated by the four arrows on top. Ten STS markers are designated per posi-
tional information of the June 2002 freeze data set of UCSC Genome Browserpublished gene encoding the putative protein KIAA1882 (Na-
(filled circles from left to right): SHGC-143082, SHGC-149465, SHGC-106957,gase et al., 2001). T1 is only partially contained within the ampli-
SHGC-85030, D8S452, D8S345, SHGC-102646, SHGC-102946, SGHC-142205,con since the 5 region of its coding sequence was found to lie
and RH36402. The position of BAC clones are indicated at the bottom.
outside of the region (Figure 1). We failed to detect by Northern Although the data shown is from single DNA TaqMan assays (each with
hybridization a smaller mRNA than the normal sized 4 kb mes- triplicate measurements with coefficient of variation [CV] of less than 3%),
each assay was performed 2 to 3 times with an average CV of 9% andsage in the highly amplified breast cancer cell line ZR-75-30,
range from less than 1% to 17%. However, the variability seen in DNA copyruling out the possibility that a truncated version of the gene
number from one probe to the next probe along the genome is sometimes
was activated in the tumors (data not shown). Furthermore, T1 greater than 17% and does not always appear to reflect true changes in
was not overexpressed in a number of other tumor samples DNA copy number. Based on unpublished results, this variability is due in
part to susceptibility of individual TaqMan probe efficiencies to currently(data not shown), strongly suggesting that it was not the gene
unknown differences in the composition of the tumor sample DNA. Based onproviding the selective pressure for genomic amplification.
this variability, several adjacent TaqMan probes were designed to delineateThe other gene was identified with the gene prediction pro-
amplicon boundaries with greater confidence.
gram GeneMachine (Makalowska et al., 2001) based on se-
quence homology to the two-pore potassium channel gene
KCNK3. A full-length cDNA for this gene, which we termed
KCNB, was cloned and we determined that its entire sequence as exhibiting overexpression if the relative value was greater
is located within the 550 kb amplicon (Figure 1). Subsequently, than 5-fold. Using Fisher’s exact test, there was a highly signifi-
other groups studying two-pore potassium channels cloned this cant correlation between DNA copy number and RNA overex-
same gene they termed TASK-3 (Kim et al., 2000; Rajan et al., pression (p  0.0001). Thus, like the HER2 oncogene (Pauletti
2000; Chapman et al., 2000). Hereafter we adopt the officially et al., 1996), the majority of cases in which KCNK9 is overex-
sanctioned gene symbol KCNK9 (http://www.gene.ucl.ac.uk/). pressed in breast and lung cancers correlates with amplification
KCNK9 was overexpressed at least 5-fold and up to over 100- or more modest gain of genomic DNA.
fold in 28 out of 64 breast cancers (44%), including all breast Antipeptide antibodies directed against the KCNK9 gene
tumors that were amplified for this region as well as tumors in product were employed to determine the frequency of overex-
which the genomic DNA was not highly amplified (Table 1). In pression in breast cancers by immunohistochemical analysis of
addition to breast cancers, KCNK9 was overexpressed in 35% normal and tumor tissue microarrays (Kononen et al., 1998).
of lung cancers (Table 1). Twenty-nine out of 71 breast tumor samples surveyed showed
To test whether there was a correlation of amplification and/ KCNK9 protein overexpression, whereas none of the 14 normal
or low-level DNA copy number increase with increased gene breast samples showed overexpression (Figure 2). These num-
expression, we classified tumors as harboring DNA copy num- bers are in close agreement to the frequency of overexpression
determined by quantitative reverse transcriptase (RT)-directedber increase if the relative value was greater than 1.5-fold, and
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KCNK9 overexpression also strongly enhanced tumorige-Table 1. Amplification and expression status of KCNK9 in human breast and
nicity of C8 cells, which were derived from primary mouse em-lung tumors
bryo fibroblasts that had been transformed with RAS and E1ARelative DNA Relative RNA
oncogenes (Figure 3B). C8 cells contain a wild-type TP53 tumorTumor type Sample ID copy number expression level
suppressor gene and as such are prone to undergo apoptosis,
Breast CHTN159 6.0 14
particularly in response to serum starvation or hypoxia (LanniBreast 90-197 5.0 66
et al., 1997; Graeber et al., 1996). Furthermore, in this model,Breast 87-634 3.9 69
Breast 88-468 2.0 27 tumors form only after a lag period that allows for the outgrowth
Breast 90-794 3.0 100 of variants that have inactivated the p53 pathway. Overexpres-
Breast 94-797 1.9 16 sion of KCNK9 shortened the time of tumor formation of theseBreast 96-342 1.5 6
TP53-containing cells by several weeks (Figure 3B). In cell cul-Breast 94-847 1.0 3
Breast 95-523 1.0 1 ture, KCNK9 overexpression in C8 cells conferred increased
Breast 96-16 1.0 0.7 cell viability in low-serum conditions (Figure 4A), although the
Lunga LU-1 2.4 100 protective effects were not as strong as that provided by TP53
Lungb LU-55 2.1 100
disruption, which protects cell almost completely (90%–100%)Lungc LU-29 2.0 45
from loss of viability induced by low-serum concentrations ofLungd LU-21 1.8 35
Lungb LU-51 1.5 12 0.1% to 0.5% (data not shown). A more dramatic effect of
Lungd LU-17 1.2 2 KCNK9 overexpression was observed when C8 cells were sub-
Lunge LU-9 1.2 1 jected to hypoxia (Figure 4B). KCNK9 overexpression allowedLungf LU-7 1.0 1
C8 cells to survive hypoxic conditions as well as TP53 disruption.Lungd LU-18 1.0 6
Lunge LU-22 0.9 0.4
DiscussionRelative DNA copy number and relative RNA expression levels were deter-
mined by real-time quantitative PCR assays, and the data shown are the
mean values of duplicate or triplicate assays. Relative values above 100 The functional studies presented here, taken together with the
are shown as 100. The coefficient of variation for relative DNA copy num- location of KCNK9 within an amplification epicenter, strongly
ber measurements was 15%, and that of relative RNA expression levels suggest that amplification and overexpression of KCNK9 pro-was 27%.
vides a selective advantage to breast cancer cells. Although itLung tumor samples are subdivided as indicated: anot classified, bsmall-cell
lung cancer, ccarcinoid, dsquamous cell carcinoma, eadenocarcinoma, has been known for years that potassium or other ion channels
and fbronchioepithelial,. can be activated by mitogens or oncogenes (Thomas and
Brugge, 1997), our results are the first indication that genetic
alteration of an ion channel gene can play a direct role in cancer.
There is a high incidence of copy number gains that affect
the 8q chromosome arm in multiple cancers, including breastPCR measurements (44%). In contrast, the human protein that
carcinomas where 8q gains occur in 40% or more of all tumorshas the closest sequence match to KCNK9, KCNK3, was not
(Struski et al., 2002). The recurrent selection for this large regionpreferentially expressed in tumor tissue as judged by immuno-
of the genome implies that multiple genes in addition to MYChistochemistry, nor was the KCNK3 gene amplified or overex-
are being selected as “driver” genes to promote tumorigenesis.pressed in breast or lung cancers, based on quantitative PCR
The data presented here identifies KCNK9 as a new protoonco-analysis (data not shown).
gene that may provide selective pressure for copy number in-We utilized immunohistochemistry to ascertain whether
creases at chromosome 8q, and in particular 8q24.3.there was a correlation of overexpression of KCNK9 with either
Our studies indicate that one potential mechanism by whichHER2 overexpression or expression of estrogen receptors. In
KCNK9 overexpression may contribute to tumorigenesis is bya set of 50 tumors, we did not detect a statistically significant
promoting cancer cell survival in the poorly oxygenated areascorrelation of KCNK9 overexpression with either estrogen re-
of solid tumors. In view of a recent report implicating KCNK9ceptor expression or HER2 overexpression (p  0.1781 and
as a key mediator of physiological effects of hypoxia in a human0.3978, respectively). Thus, there does not appear to be a spe-
lung cancer cell line (Hartness et al., 2001), it is tempting tocific requirement for KCNK9 overexpression to collaborate with
speculate that the protection from hypoxia we observed is re-these pathways.
lated to an ability of the KCNK9 channel to respond to oxygenAs the next step to ascertain whether KCNK9 is a target
levels. The ability to suppress tumorigenicity by interfering withoncogene whose amplification and overexpression could provide
a selective advantage to tumor cells, KCNK9 was deliberately the ability to respond to lowered oxygen levels has previously
overexpressed in different cell lines, and phenotypes associated been demonstrated (Kung et al., 2000). It will be important to
with tumorigenesis were assessed. KCNK9 overexpression did determine whether inhibiting KCNK9 function will disrupt re-
not transform NIH-3T3 fibroblasts or NMuMG, a cell line derived sponses to hypoxia in tumor cells, and whether this will affect
from mammary epithelial tissue (Hall et al., 1982), as judged by tumorigenicity.
growth in soft agar, growth to a higher saturation density, and
Experimental proceduresgrowth in low serum. Nor did KCNK9 overexpression in NIH-
3T3 cells induce tumor formation following implanting the cells
Tumor samples and cell lines
into athymic mice. However, three out of five mice injected with Breast and lung human tumor samples were obtained from the Cooperative
KCNK9-overexpressing NMuMG cells formed tumors within 3 Human Tissue Network and Duke University. NMuMG cells were from ATCC.
months, whereas none of the five mice that had been injected NIH-3T3, ZR-74-30, C8, and A9 cells were obtained from Cold Spring Harbor
Laboratory. C8 and A9 are isogenic transformed cells that express bothwith control NMuMG cells formed tumors (Figure 3A).
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Figure 2. Confirmation that KCNK9 is expressed preferentially in cancerous breast tissue
Representative elements of a tissue microarray stained with anti-KCNK9 antibody. Immunohistochemical stains demonstrate absent or weak staining of
normal breast (A–C) and strong staining in breast tumor samples (D–I). Shown in D–I are infiltrating ductal carcinoma, with the exception of F, which is
invasive lobular carcinoma. Magnification 200.
activated HRAS and E1A oncogenes; C8 cells contain wild-type TP53, while human genome sequence (http://www.ncbi.nlm.nih.gov/genome/seq/). The
other four BACs (34D10, 381K12, 24E21, and 4P6-B) were sequenced atA9 cells contain a homozygous deletion of TP53 (Lanni et al., 1997). Retroviral
transfection was conducted as described (Serrano et al., 1997). Genomic low-pass coverage (3 to 6) without assembly, and their alignment in the
contig shown in Figure 1 was performed by BLASTN analysis to the draftDNA was prepared using the proteinase K method, and total RNA was
extracted using the Trizol reagent according to the manufacturer’s protocol genome assembly of twenty 400 to 700 bp reads picked from each BAC at
random in addition to the BAC end sequences. The DNA sequences of these(Invitrogen, Carlsbad, CA).
reads is available from the authors. One of these BACs, which we designated
4P6-B, is a subclone of the original stab received from Research GeneticsGenomic methods
and differs in its sequence from the GenBank sequence for 4P6 (AC007870).RDA and DNA hybridization using genomic representations was performed
Exon trapping was performed with a kit from GIBCO-BRL (Invitrogen).as described (Lisitsyn et al., 1995; Lucito et al., 1998). Radiation hybrid
mapping of RDA probes was performed with the GeneBridge4 panel from
Research Genetics (Invitrogen). The CITB human BAC library, release 4, was Quantitative PCR
Fluorogenic Taqman Q-PCR probes were designed using the PrimerExpresspurchased from Research Genetics (Invitrogen) and screened as recom-
mended by the supplier with PCR primers to the RDA sequences. Both software (Applied Biosystems, Foster City, CA) and synthesized by Operon
Technologies. DNA copy number was quantified using the ABI 7700 or ABItermini of positive BAC clones were sequenced and PCR primers were
designed to allow identification of overlapping BAC clones from the same 7900 Sequence Detection Systems (Applied Biosystems, Foster City, CA).
mRNA levels of KCNK9, KCNK3, and T1 in tumors and in correspondinglibrary. Two of the six BACs (431C18 and 564L17 of accession AC007869
and AC007871, respectively) of the contig shown in Figure 1 were completely normal tissues (Clontech, Palo Alto, CA) were determined by performing
quantitative PCR with fluorogenic TaqMan probes directly following reversesequenced (Lander et al., 2001), and their sequence is part of the current
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Figure 4. Functional analysis of KCNK9
Figure 3. KCNK9 overexpression promotes tumorigenicity A: KCNK9 overexpression promotes survival in low-serum conditions. Cell
viability was measured after 2 days in medium containing different serumNormal murine mammary gland epithelial cells (NMuMG) (A) and C8 mouse
concentrations. The gray-shaded bars represent viability measurements ofembryonic fibroblast cells (B) retrovirally transfected with a KCNK9 expres-
C8 cells retrovirally transfected with a KCNK9 expression vector, and thesion vector (triangles) or empty expression vector (circles) were injected
white bars are from cells transfected with empty vector.into athymic nude mice subcutaneously for observation of tumor formation.
B: KCNK9 overexpression protects p53 cells against hypoxia. Cell viability
was measured after 3 days in medium containing different oxygen concen-
trations. The gray-shaded bars represent viability measurements of cells
maintained with normal oxygen levels, and the white bars are from cells
transcriptase reactions. Absolute mRNA levels for KCNK9 were within 50% maintained with low oxygen levels as described in Experimental Procedures.
for three different samples of normal breast tissue and three different samples C8 (p53) and A9 (p53) are isogenic and are only different in their p53
of normal lung tissues. -actin was used as a reference probe. status.
cDNA cloning
KCNK9 was PCR amplified with Pfu Turbo polymerase (Stratagene) from
ZR-75-30 cDNA using primers designed from the coding sequence predicted
normalized to the highest of the three readings of KCNK9-C8 cells in 10%by GeneMachine analysis of the DNA sequence of BAC 431C18: 5-TCATG
serum. To subject cells to hypoxia, Modular Incubator Chambers were pur-GATCCACCATGAAGAGGCAGAACGTGCGGACTCTG and 5-TTCCGAAT
chased from Billups-Rothenberg (Del Mar, CA). 12-well culture plates bearingTCTAAACGGACTTCCGGCGTTTCATCAGC. Subsequently it was cloned
100,000 cells/well in triplicate were placed in the chambers and flushed withinto BamHI/EcoRI sites of a retroviral vector, pLPC, and sequenced. Our
low-oxygen air (0.02% oxygen, 5% carbon dioxide, 94.98% nitrogen) atKCNK9 cDNA sequence contains a silent single base transition (T→C) at
20–25 l/min for 5 min. The chambers were flushed with low-oxygen air twicethe codon of amino acid Gly212 compared to our predicted KCNK9 cDNA
daily and incubated at 37	C. After 3 days, viable cells were quantified usingsequence. For cloning T1 cDNA, PCR primers to an exon trapping product
Celltiter 96 Aqueous One Solution. Relative cell viability is expressed byof BAC 431C18 (5-CGAGGTAGAAGGTGCTGGAG and 5-ACGGACAGC
normalizing all readings to highest of the three readings of KCNK9-A9 cellsCATGTGACC) were used to screen arrayed human cDNA clones purchased
exposed to normal air. Low-oxygen air tank was purchased from Generalfrom Origene (Rockville, MD) following the manufacturer’s protocol. The
Welding (Westbury, NY).resulting cDNA clone was sequenced by constructing a series of nested-
deletion mutants. The GenBank accession number for the KCNK9 cDNA
Other methodsclone is AY190605 and for the T1 cDNA clone is AY190606.
Tissue microarray slides bearing normal breast and breast tumor sections
were purchased from Imgenex (http://www.imgenex.com). Anti-TASK1 anti-Tumorigenicity, low-serum, and hypoxia assays
bodies were purchased from Chemicon (http://www.chemicon.com). PolyclonalAll functional assays were repeated at least twice with independently derived
rabbit antibodies raised against KCNK9 peptide (REEEKLKAEEIRIKGKYretroviral transfectants. For tumorigenicity assays, 2  105 of C8 cells and
NISSEDYRQ) and secondary anti-rabbit antibodies purchased from Bio-5 106 of NMuMG cells were injected s.c. into athymic mice (Crl:CD-1-nuBR
genex (http://www.biogenex.com) were used to probe tissue slides followingfrom Charles River, Wilmington, MA), with five mice for each transfectant per
the manufacturer’s protocol.individual experiment. Mice were observed weekly for tumor formation at
the injection sites and tumor sizes were determined. For survival under low-
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